Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at [Yahoo! Finance]
Structure Therapeutics Inc. (GPCR)
Company Research
Source: Yahoo! Finance
As of April 24 closing, the stock carries a strongly bullish consensus sentiment, receiving Buy ratings from all 14 analysts. Based on a 1-year median target price of $107.77, it currently offers an upside potential of almost 138%. Copyright: mikkolem / 123RF Stock Photo Back on March 16, Structure Therapeutics Inc. (NASDAQ:GPCR) released encouraging results of the Phase 2 ACCESS II study conducted on its investigational product called aleniglipron. It is an oral GLP-1 receptor agonist for use against obesity. It achieved 16.3% weight reduction when taken at 180 mg and 16% weight loss when taken at a higher dose of 240 mg at 44 weeks. The open-label extension trial reported further weight reduction up to 16.2% for the 120 mg dose after 56 weeks without any sign of weight loss plateauing. It should be mentioned that the lower 2.5 mg starting dose significantly enhanced the tolerability of the drug by lowering the rate of adverse events associated with drug discontinuations to on
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics (GPCR) was upgraded by Canaccord Genuity Group Inc. to "strong-buy".MarketBeat
- FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United StatesGlobeNewswire
- Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific SessionsGlobeNewswire
- Structure Therapeutics (GPCR) was given a new $101.00 price target by Canaccord Genuity Group Inc..MarketBeat
- Structure Therapeutics (GPCR) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
GPCR
Sec Filings
- 4/23/26 - Form 3
- 4/23/26 - Form 4
- 4/23/26 - Form DEF
- GPCR's page on the SEC website